By Hendra Lukman 
A groundbreaking study by Ludwig Cancer Research has unveiled a pioneering strategy with the potential to transform the treatment landscape for acute myelogenous leukemia (AML), a formidable blood cancer that currently carries a grim median survival rate of just 8.5 months following diagnosis. This innovative approach, detailed in the prestigious journal Nature, targets a fundamental cellular defect common across all AML subtypes, offering a dual-pronged attack that promises to overcome the disease’s notorious resistance.
The Unyielding Challenge of Acute Myelogenous Leukemia
Acute myelogenous leukemia (AML) represents a significant challenge in oncology due to its aggressive nature and the limited efficacy of current treatment paradigms for a substantial proportion of patients. Unlike many cancers driven by single genetic mutations, AML is characterized by immense genetic heterogeneity. This means that the specific genetic alterations found in leukemic cells can vary widely from one patient to another, complicating the development of targeted therapies. However, a unifying hallmark of all AML subtypes lies in a critical cellular malfunction: the impaired differentiation of myeloid progenitor cells within the bone marrow.
These myeloid progenitor cells are the precursors to various mature blood cells, including neutrophils, monocytes, and macrophages, which are essential for immune defense and tissue repair. In healthy individuals, these progenitor cells undergo a carefully orchestrated process of differentiation, maturing into their specialized functional roles. In AML, this developmental pathway is abruptly halted, leading to an accumulation of immature, undifferentiated myeloid blast cells. These abnormal cells proliferate uncontrollably in the bone marrow, crowding out healthy hematopoietic stem cells and progenitors. This disruption of normal blood cell production, known as hematopoiesis, leads to a cascade of debilitating symptoms, including anemia, increased susceptibility to infections due to a lack of functional white blood cells, and a tendency to bleed due to a deficiency in platelets. Beyond the direct impact on blood cell counts, the accumulation of these aberrant cells can infiltrate other organs, further exacerbating the disease’s severity and contributing to its rapid progression. The median survival of 8.5 months underscores the urgent need for more effective therapeutic interventions.
A Dual-Action Strategy to Restore Cellular Balance
The research team, spearheaded by Yang Shi and Amir Hosseini from Ludwig Oxford, in collaboration with Abhinav Dhall from Shi’s laboratory at Harvard Medical School and colleagues at the University of Pennsylvania and the University of Helsinki, has identified a potent combination therapy that addresses this differentiation block in two distinct, yet complementary, mechanistic ways.
"The drug combination we have identified works by activating genes that drive cell differentiation while suppressing genes that promote cell proliferation and cancer growth," explained Professor Yang Shi, a leading figure in epigenetics and a key architect of this research. This elegant dual-action mechanism aims to not only halt the uncontrolled proliferation of leukemic cells but also to steer them back towards a mature, non-cancerous state.
Building on a Legacy of Differentiation Therapy
The concept of leveraging impaired cellular differentiation as a therapeutic target is not entirely new. A notable success story in AML treatment is acute promyelocytic leukemia (APL), a distinct subtype characterized by a specific genetic translocation. For APL, a combination of all-trans retinoic acid (ATRA) and arsenic trioxide has achieved remarkable efficacy, curing approximately 95% of cases. These drugs work by effectively "shoving" the APL cells down the differentiation pathway, forcing them to mature into functional white blood cells. This success story has served as a powerful inspiration, highlighting the potential of differentiation therapy and fueling the quest for similar strategies applicable to the broader spectrum of AML subtypes.
Targeting Epigenetic Regulators: The Role of LSD1
The researchers’ strategy delves into the realm of epigenetics – the study of heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. In leukemic stem cells, aberrant gene expression programs are driven by the dysregulated activity of enzymes that chemically modify DNA and its associated proteins (histones), thereby controlling gene accessibility and activity.
One such critical enzyme is lysine-specific demethylase 1 (LSD1). First discovered by Professor Shi and his colleagues in 2004, LSD1 plays a crucial role in removing specific methyl groups from histones. These methyl groups act as crucial regulators of gene expression. In AML, LSD1 is often found at elevated levels, contributing to the maintenance of leukemic stem cells by suppressing genes that would otherwise promote their differentiation. While inhibitors targeting LSD1 have been developed and have shown promise in inducing differentiation in AML stem cells in laboratory settings, their clinical application has been hampered by significant toxicity when used as monotherapy.
Synergistic Action: The Power of Combination
Recognizing the limitations of LSD1 inhibitors alone, the research team sought to identify complementary drugs that could work synergistically. "To limit that toxicity, we thought we’d try to identify other drugs that could synergize with LSD1 inhibitors to overcome the differentiation arrest and suppress the proliferation of cancer cells," stated Dr. Amir Hosseini, a senior researcher on the study.
Their rigorous screening process, utilizing mouse models of leukemia, led them to an inhibitor of the glycogen synthase kinase 3 beta (GSK3β) enzyme. Notably, GSK3 inhibitors are already under evaluation as cancer therapeutics in ongoing clinical trials and have demonstrated a favorable safety profile, being generally well-tolerated by patients.
The pivotal discovery came when this well-tolerated GSK3 inhibitor was combined with a low dose of an LSD1 inhibitor. This combination proved remarkably effective in laboratory cultures derived from multiple AML subtypes. It not only induced the differentiation of leukemic cells but also significantly suppressed their proliferation.
Preclinical Efficacy and Safety Profile
The implications of this synergistic effect were further explored in preclinical models. The research team demonstrated that the combination therapy successfully induced differentiation in leukemic cells, effectively halting their uncontrolled growth. Crucially, this intervention also led to a significant extension in the survival of mice that had been engrafted with human AML cells, providing compelling evidence of its anti-leukemic activity.
A particularly encouraging aspect of this research is the observed selectivity of the drug combination. Experiments indicated that the combined therapy primarily targets leukemic cells, sparing healthy hematopoietic stem and progenitor cells. This targeted action is paramount for minimizing the risk of severe side effects, such as myelosuppression, which is a common concern with conventional chemotherapy for AML.
"We are also encouraged by the observation that the gene expression signature induced in leukemic cells by this combination therapy correlates with that observed in the cancer cells of AML patients who live relatively longer," added Dr. Hosseini, highlighting a potential biomarker for treatment response.
Unraveling the Molecular Mechanisms
The researchers meticulously elucidated the molecular mechanisms underpinning the efficacy of this combination therapy. Their findings reveal that the drug combination effectively rewires the gene-expression programs within leukemic cells. It suppresses the stem cell-like traits that drive the cancer’s persistence and promotes the differentiation process, essentially restoring a semblance of normal cellular development. These insights into how the therapy reconfigures cellular machinery hold significant therapeutic implications, potentially extending beyond AML to other cancers that are influenced by the overactivation of the WNT signaling pathway, a key regulator of cell growth and differentiation.
A Pathway to Clinical Translation
The current availability and established safety profiles of both the LSD1 and GSK3 inhibitors are significant advantages that expedite the potential for clinical translation. "Our findings provide compelling evidence to support the testing of this combination therapy in AML patients, especially since both of the inhibitors involved are not only available but have been developed for human use and are currently being evaluated in the clinical trials," stated Professor Shi. This means that the transition from preclinical studies to human trials could be more streamlined compared to developing entirely novel drug compounds.
Broader Implications and Future Directions
The successful identification of this combination therapy represents a significant leap forward in the fight against AML. For patients diagnosed with this aggressive disease, it offers a tangible beacon of hope, suggesting a potentially more effective and less toxic treatment option. The dual-action mechanism, targeting both proliferation and differentiation, addresses the core pathological processes of AML in a manner that has eluded previous therapeutic strategies for many subtypes.
The research also underscores the critical role of epigenetics in cancer development and highlights the power of targeting these regulatory mechanisms. The discovery that the induced gene expression signature correlates with longer survival in AML patients is a particularly exciting finding, potentially paving the way for personalized treatment approaches and the development of predictive biomarkers.
While the preclinical results are highly promising, the next crucial step involves rigorous clinical trials to confirm the safety and efficacy of this combination therapy in human patients. These trials will meticulously assess optimal dosing, treatment schedules, and potential long-term outcomes. The scientific community will be closely watching as this innovative strategy moves closer to becoming a standard of care for AML patients, potentially revolutionizing treatment and significantly improving survival rates for this devastating disease.
This research was generously supported by Ludwig Cancer Research, the National Institutes of Health, the Research Council of Finland, the Cancer Foundation Finland, the Sigrid Jusélius Foundation, the National Institute for Health Research, the Oxford Biomedical Research Centre, and Cancer Research UK. Professor Yang Shi also holds a professorship in the Nuffield Department of Medicine at the University of Oxford.
